Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 2 – Translational research

3707 - Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC)

Date

30 Sep 2019

Session

Poster Discussion 2 – Translational research

Presenters

Francesca Battaglin

Citation

Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268

Authors

F. Battaglin1, J. Xiu2, Y. Baca2, R.M. Goldberg3, A. Grothey4, A.F. Shields5, A. Seeber6, M.E. Salem7, A. Puccini8, R. Tokunaga1, M. Naseem1, H. Arai1, J. Wang1, M.D. Berger9, W. Zhang1, P.A. Philip5, J.L. Marshall10, W..M. Korn2, H.J. Lenz1

Author affiliations

  • 1 Medical Oncology, USC - Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 2 Medical Affairs, Caris Life Sciences, 85040 - Phoenix/US
  • 3 Oncology, West Virginia University Cancer Institute, 26506 - Morgantown/US
  • 4 Oncology, West Cancer Center, 38138 - Germantown/US
  • 5 Oncology, Karmanos Cancer Institute, Wayne State University, 48201 - Detroit/US
  • 6 Hematology And Oncology, Tyrolean Cancer Research Institute, University Hospital Innsbruck, 6020 - Innsbruck/AT
  • 7 Oncology, Levine Cancer Institute, 28204 - Charlotte/US
  • 8 Medical Oncology 1, IRCCS AOU San Martino - IST, Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 9 Medical Oncology Department, Inselspital - Universitatsklinik fur Medizinische Onkologie, 3010 - Bern/CH
  • 10 Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 20057 - Washington/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3707

Background

Although rare, the incidence of BM is increasing due to the improvement in metastatic CRC treatment and longer survival. Genomic analyses of small series revealed that BM can harbor potentially unique driver mutations. We aimed to comprehensively characterize the molecular profile of BM and explore the differences between BM vs other distant metastases (OM) and primary tumors (PT) in CRC.

Methods

Tumor samples from BM (n = 81), PT (n = 6898) and OM (n = 5918) were analyzed using NGS (TruSEQ on 45 genes or NextSEQ on 592 genes), in situ hybridization and immunohistochemistry (Caris Life Sciences, Phoenix, AZ). Tumor mutational burden (TMB) was calculated based on somatic nonsynonymous missense mutations, and microsatellite instability (MSI) was evaluated by NGS of known MSI loci.

Results

The most frequently mutated genes in BM were TP53 (80%), APC (73%), KRAS (68%), ARID1A (18%), PIK3CA (13%) and FBXW7 (9%). The most prevalent copy number increase was seen in CDX2 (20%), CCND2 (7%), FLT1 (7%), FLT3 (7%) and FOXO1 (7%). When compared to OM and PT, mutations in KRAS (BM: 68%, OM: 49%, PT: 48%), CDKN2A (5%, 1%, 1%), ERCC2 (2%, 0, 0) and HRAS (1%, 0, 0) were significantly higher in BM (P<.05); BRCA1 was significantly higher in BM vs OM (3 vs 1%, P=.025). Conversely, BRAF mutations trended to be lower in BM vs PT (4 vs 10%, P=.059). Overall, copy number alterations (CNA) were significantly higher in BM vs PT and OM, including CDX2, CCND2, FLT1, FOXO1, ERC1, FGF23, KDM5A, NSD3, FGFR1 (P<.05). HER2 overexpression showed a non-statistically significant trend to be higher in BM compared to PT and OM (7%, 2%, 3%, P=.064). Significantly lower rates of TMB-high (>17mut/MB) and MSI-high were seen in BM vs PT (2 vs 9% and 1 vs 8%, P=.049 and .031, respectively) but not compared to OM. No RSPO3 nor NTRK1 fusions were seen in BM (n = 5). Female gender was associated with younger age in BM (53.5 vs 62 yr, P=.0014) and OM (58.8 vs 60.2 yr, P<.0001), not seen in PT.

Conclusions

This is the largest and most extensive profiling study to investigate the molecular makeup of BM and the differences with PT and OM in CRC. Our data show distinct mutations and CNA characterizing BM and lower expression of immune related markers, supporting the rationale to develop tailored approaches to the treatment of this metastatic site.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Cancer Institute grant number P30CA014089, Gloria Borges WunderGlo Foundation-The Wunder Project, Dhont Family Foundation, San Pedro Peninsula Cancer Guild, Daniel Butler Research Fund, Call to Cure Research Fund and Fong Research Project.

Disclosure

J. Xiu: Full / Part-time employment: Caris Life Sciences. Y. Baca: Full / Part-time employment: Caris Life Sciences. R.M. Goldberg: Research grant / Funding (self), Travel / Accommodation / Expenses: Caris Life Sciences. A. Grothey: Travel / Accommodation / Expenses: Caris Life Sciences. A.F. Shields: Research grant / Funding (self), Travel / Accommodation / Expenses: Caris Life Sciences. A. Seeber: Advisory / Consultancy: Caris Life Sciences. M.E. Salem: Travel / Accommodation / Expenses: Caris Life Sciences. P.A. Philip: Travel / Accommodation / Expenses: Caris Life Sciences. J.L. Marshall: Advisory / Consultancy: Caris Life Sciences. W..M. Korn: Full / Part-time employment: Caris Life Sciences. H.J. Lenz: Travel / Accommodation / Expenses: Caris Life Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.